| Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. | |
| | |
MedLine Citation:
|
PMID: 8794826 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Vesicular monoamine transport (VMAT) inhibitors, such as reserpine and tetrabenazine, impair vesicular catecholamine storage in chromaffin cells and sympathetic neurons, thereby lowering blood pressure. Here we describe a novel action of VMAT inhibitors-blockade of L-type voltage-gated calcium channels-that may also influence catecholamine release from both PC12 rat pheochromocytoma cells and bovine adrenal chromaffin cells. When given alone, VMAT inhibitors acutely release catecholamines from chromaffin cells in a dose-dependent fashion. However, VMAT inhibitors block catecholamine secretion stimulated by either nicotinic cholinergic agonists or cell membrane depolarization, each of which rely on the opening of L-type channels; the inhibition was more potent after long-term exposure to VMAT inhibitors (IC50 < 100 nmol/L). Reserpine blocked nicotinic-stimulated catecholamine release from neurite-bearing PC12 cells. Reserpine also antagonized catecholamine release triggered by combined membrane depolarization and the dihydropyridine L-type channel agonist Bay K8644, and reserpine blocked cellular uptake of extracellular 45Ca2+ in response to nicotine. Taken together, these results indicate that VMAT inhibitors are also antagonists at L-type voltage-gated calcium channels. Classic L-type channel antagonists (verapamil or nifedipine) also exhibited the reciprocal actions; acutely, they released norepinephrine from chromaffin cells, and chronically, they depleted cellular catecholamine stores, albeit with inferior molar potency to reserpine (IC50 < 1 nmol/L). We conclude that VMAT inhibitors and L-type calcium channel antagonists exert reciprocal inhibitory actions on each other's more classic pharmacological targets. Furthermore, these novel actions are seen at concentrations of these compounds frequently taken to be specific in vitro and likely to occur during antihypertensive treatment in vivo. |
| | |
Authors:
|
M Mahata; S K Mahata; R J Parmer; D T O'Connor |
Related Documents
:
|
22521666 - Function and regulation of large conductance ca(2+)-activated k+ channel in vascular sm... 6283016 - 22na+ uptake and catecholamine secretion by primary cultures of adrenal medulla cells. 2265696 - The inhibition by pertussis and tetanus toxins of evoked catecholamine release from int... 8938256 - Depleted internal store-activated ca2+ entry can trigger neurotransmitter release in bo... 6108996 - The effects of scorpion venom toxin on the release of amino acid neurotransmitters from... 8415866 - Effects of bupivacaine on contraction and membrane potential in isolated canine papilla... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Hypertension Volume: 28 ISSN: 0194-911X ISO Abbreviation: Hypertension Publication Date: 1996 Sep |
Date Detail:
|
Created Date: 1996-11-22 Completed Date: 1996-11-22 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7906255 Medline TA: Hypertension Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 414-20 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of California, San Diego 92161, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Glands
/
cytology,
drug effects,
metabolism Animals Biological Transport / drug effects Calcium Channel Blockers / pharmacology Calcium Channels / drug effects* Cattle Chromaffin System / cytology, metabolism Membrane Glycoproteins / antagonists & inhibitors* Membrane Transport Proteins* Neuropeptides* Norepinephrine / antagonists & inhibitors*, secretion PC12 Cells Rats Reserpine / pharmacology* Tetrabenazine / pharmacology* Vesicular Biogenic Amine Transport Proteins |
| Grant Support | |
ID/Acronym/Agency:
|
N01NIMH20003/MH/NIMH NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Calcium Channel Blockers; 0/Calcium Channels; 0/Membrane Glycoproteins; 0/Membrane Transport Proteins; 0/Neuropeptides; 0/Vesicular Biogenic Amine Transport Proteins; 50-55-5/Reserpine; 51-41-2/Norepinephrine; 58-46-8/Tetrabenazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.
Next Document: Ouabainlike compound in hypertension associated with ectopic corticotropin syndrome.